Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
Immunotherapy holds great promise in cancer treatment. The challenges in advancing immunotherapies lie in patient stratification and monitoring therapy. Noninvasive detection of immune checkpoint ligand PD-L1 can serve as an important biomarker for guidance and monitoring of immunotherapy. Here in,...
Saved in:
Main Authors: | Samit Chatterjee PhD, Wojciech G. Lesniak PhD, Sridhar Nimmagadda PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-07-01
|
Series: | Molecular Imaging |
Online Access: | https://doi.org/10.1177/1536012117718459 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development of [F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide
by: Wojciech G. Lesniak PhD, et al.
Published: (2019-06-01) -
Magnetic Resonance Imaging for Characterization of a Chick Embryo Model of Cancer Cell Metastases
by: Anne Herrmann PhD, et al.
Published: (2018-10-01) -
Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab
by: Elaine M. Jagoda PhD, et al.
Published: (2019-04-01) -
Purinergic Receptors of the Central Nervous System: Biology, PET Ligands, and Their Applications
by: Hamideh Zarrinmayeh PhD, et al.
Published: (2020-06-01) -
Comment on “Surgical Margin of Resected Colorectal Liver Metastases: How Accurate Is Surgeon Prediction?”
by: Yoichiro Uchida, MD, PhD, et al.
Published: (2024-09-01)